



## Small Molecule Immuno-Oncology Drugs in Cancer Therapy

Guest Editor:

**Prof. Dr. Liwu Fu**

Department of Experimental  
Research (Cancer Institute),  
Cancer Center, Sun Yat-sen  
University, Guangzhou 510060,  
China

Deadline for manuscript  
submissions:

**closed (31 October 2022)**

### Message from the Guest Editor

Dear Colleagues,

Immuno-oncology is an emerging option to treat cancer malignancies. Immune checkpoint inhibitors represented by immunocytotoxic T lymphocyte-associated antigens 4 (CTLA-4) and programmed death receptor 1 (PD-1) monoAbs have made breakthroughs in the field of tumor immunotherapy. Additionally, small-molecule tumor immunotherapeutic agents generally exert antitumor effects by regulating the tumor immunosuppressive microenvironment or by targeting innate/adaptive immune pathways. Compared with antibody drugs, small-molecule tumor immunotherapeutic drugs can act not only on extracellular or cell-surface targets, but also through the cell membrane and other biological barriers to act on specific intracellular targets to cause antitumor immune response and have higher permeability to the tumor microenvironment. Furthermore, small-molecule tumor immunotherapeutic agents have superior pharmacokinetic properties to macromolecular antibodies, such as short half-life and good oral bioavailability, and can also balance the risk of possible side effects caused by combination therapies.





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Thomas J. Schmidt**

Institute of Pharmaceutical  
Biology and Phytochemistry,  
University of Münster,  
Corrensstrasse 48, D-48149  
Münster, Germany

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

## Contact Us

---

*Molecules* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/molecules](http://mdpi.com/journal/molecules)  
[molecules@mdpi.com](mailto:molecules@mdpi.com)  
[X@Molecules\\_MDPI](#)